Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$234K Buy
647
+2
+0.3% +$685 0.04% 206
2026
Q1
$227K Buy
645
+1
+0.2% +$356 0.04% 192
2025
Q4
$211K Buy
+644
New +$204K 0.04% 200
2025
Q2
Sell
-642
Closed -$200K 206
2025
Q1
$200K Buy
+642
New +$190K 0.06% 195
2024
Q4
Sell
-645
Closed -$208K 194
2024
Q3
$208K Hold
645
0.06% 183
2024
Q2
$201K Buy
+645
New +$189K 0.07% 170
2024
Q1
Sell
-766
Closed -$221K 159
2023
Q4
$221K Buy
+766
New +$209K 0.1% 140
2023
Q3
Sell
-967
Closed -$215K 141
2023
Q2
$215K Buy
967
+41
+4% +$9.51K 0.11% 131
2023
Q1
$224K Buy
+926
New +$227K 0.15% 117

Other funds holding AMGN

ABLE Financial Group's AMGN Position: Q2 2026 in Review

ABLE Financial Group increased its Amgen (AMGN) stake by 0.31% in Q2 2026, buying an estimated $685 and bringing the position to 647 shares worth $234K. The position accounts for 0.04% of the portfolio, ranked #206.

ABLE Financial Group first reported a position in AMGN in Q1 2023 and has held it in 9 quarters since. 956 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • ABLE Financial Group held 647 shares of Amgen worth $234K as of Q2 2026.
  • ABLE Financial Group bought 2 Amgen shares in Q2 2026, an estimated $685.
  • Amgen made up 0.04% of ABLE Financial Group's portfolio in Q2 2026, its #206 holding.
  • ABLE Financial Group first reported a position in Amgen in Q1 2023 and has held it in 9 quarters since.
  • 956 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on ABLE Financial Group's 13F filing for Q2 2026, filed 22 Jul 2026.